TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products for the treatment of lung diseases and conditions, has named Glenn Mattes as chief executive officer. Mr. Mattes brings over thirty years of business and industry leadership experience that spans a wide range of businesses and therapeutic categories.

Robert Mills, TFF Pharmaceuticals’ chairman of the Board, said, “With Glenn at the helm as our CEO, we have honored our promise to investors to build a dynamic leadership team. He is the right strategic fit for taking TFF Pharmaceuticals from inception to a strong commercial success. Glenn has a proven track record of growing and advancing transformational pharmaceutical therapeutics to market leadership worldwide.”

TFF Pharmaceuticals recently closed an offering of its Series A Convertible Preferred Stock, resulting in gross proceeds of $14 million. The funding will be used to accelerate development of the company’s pipeline of advanced performance dry powder drugs for the treatment of pulmonary diseases and conditions, such as lung transplant recovery, severe asthma, COPD, and pulmonary infections.

“I am excited to begin my new role at TFF Pharmaceuticals,” said Mr. Mattes. “Our breakthrough Thin Film Freezing proprietary platform and leading-edge product portfolio address lung diseases and conditions that cause suffering and mortality throughout the world. We intend to develop and commercialize drug products that will have a positive impact globally on public health as well as significant long-term returns for our investors.”